Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
D000813:Anilides / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003534:Cyproterone / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D008297:Male; D008535:Megestrol / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000187:drug effects*; D011966:Receptors, LHRH
D000813:Anilides; D011956:Receptors, Cell Surface; D011966:Receptors, LHRH; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D003534:Cyproterone; D008535:Megestrol